The company, in a statement, said “it has received approval from the United States Food & Drug Administration for Lamivudine and Zidovudine Tablets USP, 150 mg/ 300 mg”.
The drug belongs to a group of anti-viral medicines, also known as anti-retrovirals, and is used with other anti-retroviral medicines to treat HIV infection in adults and children.
The Lamivudine and Zidovudine tablets reduce the level of HIV in body and keep it low, the company said.
“The product will be manufactured at the company’s oral dosage facility in Bangalore and marketed by Strides in the US market. The product will be launched in the markets immediately,” the statement read.
The pharma company shared IMS data which estimate the US market for Lamivudine and Zidovudine tablets at approximately USD 120 million.
The scrip of Strides Arcolab was trading at Rs 1,067.7, up 4.26 per cent, at 1127 hours on BSE today.
PTI